| |
| Incremental cost-effectiveness of the pre- and post-bevacizumab eras of metastatic colorectal cancer therapy in British Columbia, Canada |
| Hedden L, Kennecke H, Villa D, Johnston K, Speers C, Kovacic L, Renouf DJ, Peacock S |
|
|
| |
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Hedden L, Kennecke H, Villa D, Johnston K, Speers C, Kovacic L, Renouf DJ, Peacock S. Incremental cost-effectiveness of the pre- and post-bevacizumab eras of metastatic colorectal cancer therapy in British Columbia, Canada. European Journal of Cancer 2012; 48(13): 1969-1976 Indexing Status Subject indexing assigned by NLM MeSH Aged; Angiogenesis Inhibitors /economics /therapeutic use; Antibodies, Monoclonal, Humanized /economics /therapeutic use; Antineoplastic Combined Chemotherapy Protocols /economics; Bevacizumab; British Columbia; Colorectal Neoplasms /drug therapy /economics /mortality /pathology; Cost-Benefit Analysis; Female; Humans; Male; Markov Chains; Neoplasm Metastasis; Quality-Adjusted Life Years; Sensitivity and Specificity AccessionNumber 22012032343 Date bibliographic record published 04/01/2013 |
| |
|
|
